Literature DB >> 3292720

Stereotaxic implantation of dispersed cell suspensions into brain. A systematic appraisal of cell placement and survival.

R J Plunkett1, R J Weber, E H Oldfield.   

Abstract

The application of several recent advances in cell biology, brain implantation, and cell-mediated tumor immunotherapy requires successful and reproducible placement of viable cell suspensions into brain. Stereotaxic implantation is being used to inject cytotoxic lymphocytes into gliomas and to replace dopaminergic cells in parkinsonian models. Systematic assessment of the factors that influence success in implantation of cell suspensions into solid tissues is needed. A model was developed for investigation of stereotaxic implantation using radiolabeled rat lymphokine-activated killer (LAK) cells. Anesthetized rats received microliter injections of cell suspension into the right caudate nucleus. The injection volume, cell concentration, infusion rate, and needle size were varied systematically. The animals were sacrificed 1 hour after injection; the brain was removed and sectioned, and the radioactivity was counted. Three aliquots of the suspension were injected into counting tubes for control analysis. Recovery of radioactivity was expressed as the percent of mean counts per minute (cpm) in the right frontal lobe/mean cpm in the three control tubes. To assess the viability of implanted cells, the right frontal region was mechanically dissociated in media and centrifuged, and the pellet and supernatant were counted. By using small needles and slow infusion of volumes of 10 microliters or less, 85% to 90% of the radioactivity was recovered in the caudate nucleus. At least half of the implanted cells were viable. Consistent, accurate implantation of dispersed cells into brain over a range of volumes, cell concentrations, infusion rates, and needle sizes was achieved.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3292720     DOI: 10.3171/jns.1988.69.2.0228

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  4 in total

Review 1.  Immunotherapy for malignant glioma using human recombinant interleukin-2 and activated autologous lymphocytes. A review of pre-clinical and clinical investigations.

Authors:  R E Merchant; M D Ellison; H F Young
Journal:  J Neurooncol       Date:  1990-04       Impact factor: 4.130

2.  Morphometrical characterization of two glioma models in the brain of immunocompetent and immunodeficient rats.

Authors:  M Saini; M Bellinzona; F Meyer; G Cali; M Samii
Journal:  J Neurooncol       Date:  1999-03       Impact factor: 4.130

3.  Stereotaxic Implantation of F98 Cells in Fischer Rats: A Syngeneic Model to Investigate Photodynamic Therapy Response in Glioma.

Authors:  Anne-Laure Bulin; Jean-François Adam; Hélène Elleaume
Journal:  Methods Mol Biol       Date:  2022

4.  Radiosensitizing effect of estramustine in malignant glioma in vitro and in vivo.

Authors:  A T Bergenheim; B Zackrisson; J Elfverson; G Roos; R Henriksson
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.